The Only Industry-Specific Event for
Respiratory Drug Developers

Consolidate Translational Understanding & Data from the Last 18-24 Months

Understand Clinical Trial Design & Trackable Trial Endpoints for Heterogenous Disease Presentations

Evaluate Therapeutic Opportunities Including Targeting Complement Fragments & Harnessing MSCs

Reimagine Clinical Trial Design, Harness Patient Phenotyping, Explore Innovative Therapeutic Modalities, & Learn New Mechanisms of Action to Transform ARDS Drug Development

Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2023 event, please get in touch at info@hansonwade.com

Navigate clinical trial design to meet both early and late-stage endpoints, discover therapeutic opportunities with patient biomarkers and phenotyping, and uncover the latest clinical trial advancements to benchmark your therapeutic modality, at the 2nd ARDS Drug Development Summit. This is the only translational conference for drug developers to learn from and move past the clinical trial setbacks.

Developed exclusively to define and advance the therapeutic opportunity and consolidate translational data in ARDS, join over 100+ inflammation and respiratory experts including Mesoblast, Healios, Biomarck Pharmaceuticals, Edesa Biotech, Tetra Biopharma, Apeptico, Aptarion Biotech, and many more.

Don't miss this unique opportunity to deep dive into the hottest ARDS research, ensuring your team gains actionable insights to supercharge your drug development and bring life-changing therapies for ARDS patients around the world.

60+
Experienced Attendees

20+
Expert
Speakers

15+
Dedicated Sessions

2
Interactive Workshops

3
Unmissable Days

2022 World Class Speaker Faculty Included:

Alistair Wheeler

Alistair Wheeler
Chief Medical Officer
BioMarck Pharmaceuticals

silviu

Silviu Itescu
Chief Executive Officer
Mesoblast

Axel Vater Portrait

Axel Vater
Founder & Chief Scientific Officer
Aptarion Biotech

bernard

Bernhard Fischer
Chief Executive Officer
Apeptico

ritu

Ritu Lal
Chief Executive Officer
Gen1E Lifesciences

Taylor Thompson

B. Taylor Thompson
Professor of Medicine
Massachusetts General Hospital
Harvard Medical School

Why Does the Industry Want to Attend?

"It is extremely important to translate understanding to the molecular knowledge of the etiology of ARDS to the bedside for new treatments for ARDS"
Virginia University

"I am looking forward to the exchange of clinical information with other drug developers and the presentation of essential information towards understanding of ARDS and COVID-19"
Apeptico

Other Events in the Series